Evidence map›Paper›PMID 28591834›Full record

ArticleCerebral cortex (New York, N.Y. : 1991)2018

Cholinergic Grb2-Associated-Binding Protein 1 Regulates Cognitive Function.

Nan-Nan Lu, Chao Tan, Ning-He Sun, Ling-Xiao Shao, Xiu-Xiu Liu, Yin-Ping Gao, Rong-Rong Tao, Quan Jiang, Cheng-Kun Wang, Ji-Yun Huang and 6 more

Abstract read
In one paragraph

Article in Cerebral cortex (New York, N.Y. : 1991), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nan-Nan LuCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Chao TanCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Ning-He SunCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Ling-Xiao ShaoCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Xiu-Xiu LiuCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Yin-Ping GaoCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Rong-Rong TaoCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Quan JiangCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Cheng-Kun WangCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Ji-Yun HuangCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
Kui ZhaoDepartment of PET Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Guang-Fa WangDepartment of PET Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zhi-Rong LiuDepartment of Neurology, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
Kohji FukunagaDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-ku, Sendai, Japan.
Ying-Mei LuSchool of Medicine, Zhejiang University City College, Hangzhou, Zhejiang, China.
Feng HanCollege of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.

Funding

INTEGRATED CENTER FOR IN VIVO MICROSCOPYP41EB015897 · NIBIB · DUKE UNIVERSITY · PI JOHNSON, GEORGE ALLAN · 2012 to 2017
$7.4M
NIBIB NIH HHS P41 EB015897
6 · The paper itself

Abstract

Grb2-associated-binding protein 1 (Gab1) is a docking/scaffolding molecule known to play an important role in cell growth and survival. Here, we report that Gab1 is decreased in cholinergic neurons in Alzheimer's disease (AD) patients and in a mouse model of AD. In mice, selective ablation of Gab1 in cholinergic neurons in the medial septum impaired learning and memory and hippocampal long-term potentiation. Gab1 ablation also inhibited SK channels, leading to an increase in firing in septal cholinergic neurons. Gab1 overexpression, on the other hand, improved cognitive function and restored hippocampal CaMKII autorphosphorylation in AD mice. These results suggest that Gab1 plays an important role in the pathophysiology of AD and may represent a novel therapeutic target for diseases involving cholinergic dysfunction.

Indexed as

Action PotentialsAdaptor Proteins, Signal TransducingAged, 80 and overAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsBrainCalcium-Calmodulin-Dependent Protein Kinase Type 2Cerebral CortexCholine O-AcetyltransferaseCholinergic NeuronsCognitionDisease Models, AnimalFemaleGene Expression RegulationHumansAdaptor Proteins, Signal TransducingAmyloid beta-Protein PrecursorCalcium-Calmodulin-Dependent Protein Kinase Type 2Choline O-AcetyltransferaseGab1 protein, mousePhosphoproteinsPresenilin-1

Identifiers

PMID28591834
PMCPMC7189983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.